A study of lovastatin and <scp>l</scp>-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression
Andy Wijaya, Yi Wang, Dan Tang, Yuan Zhong, Boyan Liu, Yan Meng, Quhui Jiu, Wei Wu, Guixue Wang
Abstract
confirmed using DAF-FM DA, augment eNOS and p-eNOS mRNA and protein levels, and suppress the ki67 proliferation marker in VSMCs; in addition, it lowers the total cholesterol level of blood plasma in C57BL/6 mice. Moreover, PLGA can protect the compound delivered and enhance the bioavailability to reach and get released in the blood circulation after oral administration. Collectively, our results endow a safe and efficient nanomedicine outcome, specifically with potential for AS management.
Topics & Concepts
EnosNitric oxideNanomedicineLovastatinBioavailabilityPLGAPharmacologyNitric Oxide Synthase Type IIIIn vivoChemistryNitric oxide synthaseIn vitroMedicineBiochemistryMaterials scienceInternal medicineBiologyCholesterolNanotechnologyNanoparticleBiotechnologyCell Adhesion Molecules ResearchProtease and Inhibitor MechanismsNeuropeptides and Animal Physiology